INCB013739
DrugINCB013739 5 mg QD tablet
NCT Number: NCT00698230
Determine the effect of treatment with INCB013739 administered as an 'add-on' to metformin therapy in type 2 diabetic subjects on safety and tolerability and glycemic control.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Phase 2
Carolina, Puerto Rico
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
INCB013739 5 mg QD tablet
Orally once daily tablet
Time frame: Baseline and Week 12 (or early termination study visit)
Time frame: Baseline and Week 12 (or early termination study visit)
Incyte Corporation
Industry
Randomized Study to Evaluate the Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetic Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06626646
Arterial Occlusive Diseases, Arteriosclerosis
North York, Ontario, Canada
View Trial DetailsNCT07005362
Artificial Intelegence, Behavior
Aurora, Colorado, United States
View Trial DetailsNCT06945419
Body Weight, Body Weight Changes
Daytona Beach, Florida, United States
View Trial DetailsNCT06457139
Diabetes Mellitus, Diabetes Mellitus, Type 2
Worcester, Massachusetts, United States
View Trial Details